PharmEasy’s Valuation Dips Significantly But Expected To Recover Through Acquisitions

  • PharmEasy’s valuation is projected to drop by 90%, going from $5.5bn to a mere $500-600m.
  • Despite this, investors remain confident and expect the company to recover over the next two years, buoyed by profitable acquisitions such as Thyrocare.
  • However, corporate debts accumulated by PharmEasy, including a $285m loan from Goldman Sachs, bring an additional level of financial uncertainty.
Join 2 million subscribers

A curated newsletter that summarizes the important news at the intersection of Global tech, India Tech and AI.

Delivered 8 AM. Daily.
nextbigwhat We would like to show you notifications for the latest news and updates.
Allow Notifications